Does concurrent in utero exposure to buprenorphine and antidepressant medications influence the course of neonatal abstinence syndrome?
OBJECTIVE
To determine whether concurrent in utero exposure to buprenorphine and antidepressants impacts the course of neonatal abstinence syndrome (NAS) in infants.


METHODS
A retrospective cohort study of 148 infants who were exposed to buprenorphine during pregnancy. Univariate and bivariate analyses were used to examine associations between concurrent maternal use of buprenorphine and antidepressants as compared to maternal use of buprenorphine alone.


RESULTS
The time to onset of NAS resolution was significantly longer in infants exposed to both buprenorphine and antidepressants during pregnancy when compared to those exposed to buprenorphine alone (129.8 h versus 70.2 h, p = 0.042).


CONCLUSIONS
Women who are prescribed both antidepressants and buprenorphine during pregnancy should be counseled about the possibility of a prolonged course of neonatal abstinence syndrome.
a Dartmouth Medical School, Maine Dartmouth Family Medicine Residency , Waterville , ME , USA .
Alane B
AB
O'Connor
b Department of Mathematics and Statistics , Colby College , Waterville , ME , USA .|c School of Community and Population Health, University of New England , Portland , ME , USA , and.
Liam
L
O'Brien
d Swedish Family Medicine Residency Program Cherry Hill, University of Washington , Seattle , WA , USA.
William A
WA
Alto
d Swedish Family Medicine Residency Program Cherry Hill, University of Washington , Seattle , WA , USA.
Jacqueline
J
Wong
D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects*; D002047:Buprenorphine / Q000009:adverse effects*; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D009294:Narcotics / Q000009:adverse effects*; D009357:Neonatal Abstinence Syndrome / Q000209:etiology*; D058850:Opiate Substitution Treatment / Q000009:adverse effects*; D011247:Pregnancy; D012189:Retrospective Studies
D000928:Antidepressive Agents; D009294:Narcotics; D002047:Buprenorphine
Antidepressants; buprenorphine; opioid use disorders; pregnancy